Tisagenlecleucel
Kymriah (tisagenlecleucel) is a cell pharmaceutical. Tisagenlecleucel was first approved as Kymriah on 2018-08-22. It has been approved in Europe to treat large b-cell lymphoma diffuse and precursor b-cell lymphoblastic leukemia-lymphoma.
| Trade Name | Kymriah |
|---|---|
| Common Name | Tisagenlecleucel |
| Indication | large b-cell lymphoma diffuse, precursor b-cell lymphoblastic leukemia-lymphoma |
| Drug Class |
